Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: chemokine receptor antagonists - ChemoCentryx

Next Previous
X
Search
Drug Profile

Research programme: chemokine receptor antagonists - ChemoCentryx

Alternative Names: CCX 6239; CCX 9664; CCX 991; CCX-662; CCX650

Latest Information Update: 01 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemoCentryx
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Skin disorder therapies; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR9 receptor antagonists; Chemokine receptor antagonists; CXCR4 receptor antagonists; CXCR7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Metabolic disorders

Highest Development Phases

  • No development reported Atopic dermatitis; Glioblastoma; Inflammatory bowel diseases; Metabolic disorders; Pustular psoriasis

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for preclinical development in Pustular psoriasis in USA (PO)
  • 30 Apr 2020 Preclinical development is ongoing in USA (ChemoCentryx pipeline, April 2020)
  • 28 May 2018 No recent reports of development identified for preclinical development in Atopic-dermatitis in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top